Orgenesis (NASDAQ:ORGS – Get Free Report) and Roivant Sciences (NASDAQ:ROIV – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.
Risk & Volatility
Orgenesis has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.
Earnings and Valuation
This table compares Orgenesis and Roivant Sciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Orgenesis | $662,000.00 | 18.85 | -$55.36 million | N/A | N/A |
| Roivant Sciences | $122.59 million | 63.85 | $4.35 billion | ($0.15) | -73.13 |
Institutional and Insider Ownership
22.6% of Orgenesis shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 5.7% of Orgenesis shares are held by company insiders. Comparatively, 7.9% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings for Orgenesis and Roivant Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Orgenesis | 0 | 0 | 0 | 0 | 0.00 |
| Roivant Sciences | 0 | 1 | 5 | 1 | 3.00 |
Roivant Sciences has a consensus target price of $18.08, indicating a potential upside of 64.84%. Given Roivant Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Orgenesis.
Profitability
This table compares Orgenesis and Roivant Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Orgenesis | -3,827.81% | N/A | -130.18% |
| Roivant Sciences | -119.54% | -14.05% | -12.81% |
Summary
Roivant Sciences beats Orgenesis on 12 of the 13 factors compared between the two stocks.
About Orgenesis
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
